Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On May 13, 2024, Imunon, Inc. (IMNN) announced financial results for the first quarter of 2024 and provided a business update.</li><li>The company is on track to report topline results from the OVATION 2 trial of IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy as a first-line treatment of locally advanced ovarian cancer, in mid-2024.</li><li>In addition, the company announced it has activated the first site for patient recruitment for the Phase 1 study of IMNN-101, a seasonal COVID-19 vaccine candidate.</li></ul>

On May 13, 2024, Imunon, Inc. (IMNN) announced financial results for the first quarter of 2024 and provided a business update.The company is on track to report topline results from the OVATION 2 trial of IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy as a first-line treatment of locally advanced ovarian cancer, in mid-2024.In addition, the company announced it has activated the first site for patient recruitment for the Phase 1 study of IMNN-101, a seasonal COVID-19 vaccine candidate.

IMNN: Results from OVATION 2 Study in Mid-2024 

United States

IMUNON, Inc. operates as a clinical stage biotechnology company. The Company focuses on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Imunon (IMNN US)

IMNN: Results from OVATION 2 Study in Mid-2024

On May 13, 2024, Imunon, Inc. (IMNN) announced financial results for the first quarter of 2024 and provided a business update. The company is on...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)